Silvia Menéndez

Silvia Menéndez

Auto-generated profile, based on publicly available information

Silvia Menéndez

Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2014 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ICIsrael Cañadas
Israel Cañadas
FRFederico Rojo
Federico Rojo
ÁTÁlvaro Taus
Álvaro Taus
OAOriol Arpí
Oriol Arpí
MAMontserrat Arumí-Uría
Montserrat Arumí-Uría
EAEdurne Arriola
Edurne Arriola
Purpose: Met receptor phosphorylation is associated with poor prognosis in human small cell lung cancer (SCLC). The aim of our work was to investigate the effects of hepatocyte growth factor (HGF)/Met–mediated epithelial-to-mesenchymal transition (EMT) in SCLC and to evaluate the role of Met inhibition in mesenchymal/chemorefractory SCLC models.

1 March 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
AMAura Muntasell
Aura Muntasell
FRFederico Rojo
Federico Rojo
SSSonia Servitja
Sonia Servitja
CRCarlota Rubio-Perez
Carlota Rubio-Perez
MCMariona Cabo
Mariona Cabo
JAJoan Albanell
Joan Albanell
Purpose: We investigated the value of tumor-infiltrating NK (TI-NK) cells and HLA class I tumor expression as biomarkers of response to neoadjuvant anti-HER2 antibody–based treatment in breast cancer. Experimental Design: TI-NK cells and HLA-I were determined by IHC in pretreatment tumor biopsies from two cohorts of patients with HER2-positive breast cancer [discovery cohort (n = 42) and validation cohort (n = 71)]. Tumor-infiltrating lymphocytes (TIL) were scored according to international guidelines. Biomarker association with pathologic complete response (pCR) and disease-free survival (DFS) was adjusted for prognostic factors. Gene set variation analysis was used for determining immune cell populations concomitant to NK-cell enrichment in HER2-positive tumors from the Cancer Genome Atlas (n = 190). Results: TI-NK cells were significantly associated with pCR in the discovery cohort as well as in the validation cohort (P < 0.0001), independently of clinicopathologic factors. A ≥3 TI-NK cells/50x high-power field (HPF) cutoff predicted pCR in the discovery and validation cohort [OR, 188 (11–3154); OR, 19.5 (5.3–71.8)]. Presence of TI-NK cells associated with prolonged DFS in both patient cohorts [HR, 0.07 (0.01–0.6); P = 0.01; HR, 0.3 (0.08–1.3); P = 0.1]. NK-, activated dendritic- and CD8 T-cell gene expression signatures positively correlated in HER2-positive tumors, supporting the value of NK cells as surrogates of effective antitumor immunity. Stratification of patients by tumor HLA-I expression identified patients with low and high relapse risk independently of pCR. Conclusions: This study identifies baseline TI-NK cells as an independent biomarker with great predictive value for pCR to anti-HER2 antibody–based treatment and points to the complementary value of tumor HLA-I status for defining patient prognosis independently of pCR.

14 November 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MSMohammadA Sabbaghi
MohammadA Sabbaghi
GGGabriel Gil-Gómez
Gabriel Gil-Gómez
CGCristina Guardia
Cristina Guardia
SSSonia Servitja
Sonia Servitja
OAOriol Arpí
Oriol Arpí
JAJoan Albanell
Joan Albanell
Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: HER2-positive breast cancer cells (HCC1954, HCC1419, SKBR3, and BT474) were treated in a pulse-fashion with T-DM1 to induce a resistant phenotype. Cellular and molecular effects of T-DM1 in parental versus resistant cells were compared. CDK1 kinase activity and cyclin B1 expression were assayed under various conditions. Genetic modifications to up- or downregulate cyclin B1 were conducted. Effects of T-DM1 on cyclin B1 levels, proliferation, and apoptosis were assayed in human HER2-positive breast cancer explants.Results: We obtained three cell lines with different levels of acquired T-DM1 resistance (HCC1954/TDR, HCC1419/TDR, and SKBR3/TDR cells). HER2 remained amplified in the resistant cells. Binding to HER2 and intracellular uptake of T-DM1 were maintained in resistant cells. T-DM1 induced cyclin B1 accumulation in sensitive but not resistant cells. Cyclin B1 knockdown by siRNA in parental cells induced T-DM1 resistance, while increased levels of cyclin B1 by silencing cdc20 partially sensitized resistant cells. In a series of 18 HER2-positive breast cancer fresh explants, T-DM1 effects on proliferation and apoptosis paralleled cyclin B1 accumulation.Conclusions: Defective cyclin B1 induction by T-DM1 mediates acquired resistance in HER2-positive breast cancer cells. These results support the testing of cyclin B1 induction upon T-DM1 treatment as a pharmacodynamic predictor in HER2-positive breast cancer. Clin Cancer Res; 23(22); 7006–19. ©2017 AACR.

30 January 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
RRRaúl Rincón
Raúl Rincón
ICIon Cristóbal
Ion Cristóbal
SZSandra Zazo
Sandra Zazo
OAOriol Arpí
Oriol Arpí
SMSilvia Menéndez
Silvia Menéndez
FRFederico Rojo
Federico Rojo
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

29 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ETEduardo Tormo
Eduardo Tormo
SBSandra Ballester
Sandra Ballester
AAAnna Adam-Artigues
Anna Adam-Artigues
OBOctavio Burgués
Octavio Burgués
EAElisa Alonso
Elisa Alonso
PEPilar Eroles
Pilar Eroles
The mechanisms of chemotherapy resistance in triple negative breast cancer remain unclear, and so, new molecules which might mediate this resistance could optimize treatment response. Here we analyzed the involvement of the miRNA-449 family in the response to doxorubicin. The cell viability, cell-cycle phases, and the expression of in silico target genes and proteins of sensitive/resistant triple negative breast cancer cell lines were evaluated in response to doxorubicin treatment and after gain/loss of miRNAs-449 function achieved by transient transfection. Triple negative breast cancer patients were selected for ex vivo experiments and to evaluate gene and miRNAs expression changes after treatment, as well as survival analysis by Kaplan-Meier. Doxorubicin treatment upregulated miRNAs-449 and DNA-damage responder factors E2F1 and E2F3 in triple negative breast cancer sensitive breast cancer cells, while expression remained unaltered in resistant ones. In vitro overexpression of miRNAs-449 sensitized cells to the treatment and significantly reduced the resistance to doxorubicin. These changes showed also a strong effect on cell cycle regulation. Finally, elevated levels of miRNA-449a associated significantly with better survival in chemotherapy-treated triple negative breast cancer patients. These results reveal for the first time the involvement of the miRNA-449 family in doxorubicin resistance and their predictive and prognostic value in triple negative breast cancer patients.

1 November 2017 in Clinical Lung Cancer
Verified
Journal Article
Closed access
DCDavid Casadevall
David Casadevall
SCSergi Clavé
Sergi Clavé
ÁTÁlvaro Taus
Álvaro Taus
MHMax Hardy-Werbin
Max Hardy-Werbin
PRPedro Rocha
Pedro Rocha
EAEdurne Arriola
Edurne Arriola